The SKATE™ study: An open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy

Epilepsy Research

Volumn 76, Issue 1, 2007, Pages 6-14

  Steinhoff, Bernhard J ^a   Somerville, Ernest R ^b   Van Paesschen, Wim ^c   Ryvlin, Philippe ^d   Schelstraete, Isabelle ^e  

^a Epilesiezentrum Kork   (Germany)

^b PRINCE OF WALES HOSPITAL   (Australia)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d HÔPITAL NEUROLOGIQUE   (France)

^e UCB PHARMA   (Belgium)

Author keywords

Adjunctive therapy; Antiepileptic drug; Clinical practice; Levetiracetam; Partial epilepsy

Indexed keywords

ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; ETIRACETAM; LAMOTRIGINE; PHENYTOIN; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; DRUG DERIVATIVE; PIRACETAM;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ACUTE PSYCHOSIS; ADD ON THERAPY; ADOLESCENT; ADULT; AGED; AGGRESSION; ARTICLE; ASTHENIA; BIPOLAR DISORDER; CLINICAL PRACTICE; CLINICAL TRIAL; CONFUSION; CONVULSION; DELIRIUM; DEPRESSION; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FALLING; FATIGUE; FEMALE; FOCAL EPILEPSY; HEADACHE; HOSTILITY; HUMAN; HYPERTENSION; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; NAUSEA; PARANOIA; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; PSYCHOSIS; QUALITY OF LIFE; SEIZURE; SIDE EFFECT; SOMNOLENCE; SUICIDAL IDEATION; TREMOR; WALKING DIFFICULTY; DEMOGRAPHY; DRUG ADMINISTRATION; DRUG COMBINATION; HEALTH STATUS; INTERNATIONAL COOPERATION; MIDDLE AGED; MULTICENTER STUDY; RETROSPECTIVE STUDY; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTICONVULSANTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EPILEPSIES, PARTIAL; FEMALE; HEALTH STATUS; HUMANS; INTERNATIONAL COOPERATION; MALE; MIDDLE AGED; PIRACETAM; QUALITY OF LIFE; RESIDENCE CHARACTERISTICS; RETROSPECTIVE STUDIES; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 34547828806     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2007.06.002     Document Type: Article

References (36)

1. Ben-Menachem E., Falter U., and The European Levetiracetam Study Group. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia 41 (2000) 1276-1283
2. Ben-Menachem E., and Gilland E. Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy. Seizure 12 (2003) 131-135
3. Beran R.G., Berkovic S.F., Black A.B., Danta G., Hiersemenzel R., Schapel G.J., and Vajda F.J.E. Efficacy and safety of levetiracetam 1000-3000 mg/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study. Epilepsy Res. 63 (2005) 1-9
4. Berkovic, S.F., Knowlton, R.C., Leroy, R.F., Schiemann, J., Falter, U., 2007. On behalf of the Levetiracetam NO1057 Study Group. Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology [Epub ahead of print].
5. Betts T., Waegemans T., and Crawford P. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy. Seizure 9 (2000) 80-87
6. Betts T., Yarrow H., Greenhill L., and Barrett M. Clinical experience of marketed levetiracetam in an epilepsy clinic-a one year follow up study. Seizure 12 (2003) 136-140
7. Beyenburg S., Bauer J., and Reuber M. New drugs for the treatment of epilepsy: a practical approach. Postgrad. Med. J. 80 (2004) 581-587
8. Boon P., Chauvel P., Pohlmann-Eden B., Otoul C., and Wroe S. Dose-response effect of levetiracetam 1000 and 2000 mg/day in partial epilepsy. Epilepsy Res. 48 (2002) 77-89
9. Brodie M.J., Perucca E., Ryvlin P., Ben-Menachem E., Meencke H.-J., and Levetiracetam Monotherapy Study Group. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 68 (2007) 402-408
10. Cereghino J.J. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 55 (2000) 236-242
11. Commission on Classification and Terminology of the International League against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981, 22, 489-501.
12. Cramer J.A., Perrine K., Devinsky O., and Meador K. A brief questionnaire to screen for quality of life in epilepsy: the QOLIE-10. Epilepsia 37 (1996) 577-582
13. Cramer J., Arrigo C., and Van Hammée G. Patient-rated priorities and relationship to distress in health-related quality of life domains: the QOLIE-31-P and QOLIE-10-P in a long-term levetiracetam study. Epilepsia 43 Suppl. 8 (2002) 199
14. Cramer J.A., De Rue K., Devinsky O., Edrich P., and Trimble M.R. A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. Epilepsy Behav. 4 (2003) 124-132
15. Crowder K.M., Gunther J.M., Jones T.A., Hale B.D., Zhang H.Z., Peterson M.R., Scheller R.H., Chavkin C., and Bajjalieh S.M. Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). PNAS 96 (1999) 15268-15273
16. Depondt C., Yuen A.W., Bell G.S., Mitchell T., Koepp M.J., Duncan J.S., and Sander J.W. The long term retention of levetiracetam in a large cohort of patients with epilepsy. J. Neurol. Neurosurg. Psychiatry 77 (2006) 101-103
17. Ferrendelli J.A., French J., Leppik I., Morrell M.J., Herbeuval A., Han J., and Magnus L. Use of levetiracetam in a population of patients aged 65 years and older: a subset analysis of the KEEPER trial. Epilepsy Behav. 4 (2003) 702-709
18. French J., Edrich P., and Cramer J.A. A systematic review of the safety profile of levetiracetam: a new antiepileptic drug. Epilepsy Res. 47 (2001) 77-90
19. Genton P., Sadzot B., Fejerman N., Peltola J., Despland P.-A., Steinhoff B., Rektor I., Wroe S., Maubrey M.-C., Vandervelden C., van Hammée G., Schlit A.-F., and van Paesschen W. Levetiracetam in a broad population of patients with refractory epilepsy: interim results of the SKATE trial. Acta Neurol. Scand. 113 (2006) 387-394
20. Gidal B.E., Baltes E., Otoul C., and Perucca E. Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: a pooled analysis of data from randomized clinical trials. Epilepsy Res. 64 (2005) 1-11
21. Glauser T.A., Ayala R., Elterman R.D., Mitchell W.G., Van Orman C.B., Gauer L.J., et al. A double-blind randomized placebo-controlled trial of levetiracetam adjunctive therapy in children with partial seizures. Neurology 66 (2006) 1654-1660
22. ICH E6 Note for Guidance on Good Clinical Practice (CPMP/ICH/135/95), 1996. EMEA; July.
23. Kwan P., and Brodie M.J. Early identification of refractory epilepsy. N. Engl. J. Med. 342 (2000) 314-319
24. Lambrechts D.A.J.E., Sadzot B., van Paesschen W., van Leusden J.A., Carpay J., Bourgeois P., et al. Efficacy and safety of levetiracetam in clinical practice: results of the SKATE™ trial from Belgium and The Netherlands. Seizure 15 (2006) 434-442
25. Levy R.H., Ragueneau-Majlessi I., and Baltes E. Repeated administration of the novel antiepileptic agent levetiracetam does not alter digoxin pharmacokinetics and pharmacodynamics in healthy volunteers. Epilepsy Res. 46 (2001) 93-99
26. Lynch B.A., Lambeng N., Nocka K., Kensel-Hammes P., Bajjalieh S.M., Matagne A., and Fuks B. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 9861-9866
27. Meencke H.J., and Buyle S. Assessment of a dose-response relationship of levetiracetam. Eur. J. Neurol. 13 (2006) 942-946
28. Morrell M.J., Leppik I., French J., et al. The KEEPER trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study. Epilepsy Res. 54 (2003) 153-161 (Corrigendum: 2003. Epilepsy Res. 56, 209-210)
29. Patsalos P.N. Clinical pharmacokinetics of levetiracetam. Clin. Pharmacokinet. 43 (2004) 707-724
30. Ragueneau-Majlessi I., Levy R.H., and Janik F. Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women. Epilepsia 43 (2002) 697-702
31. Ragueneau-Majlessi I., Levy R.H., and Meyerhoff C. Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin. Epilepsy Res. 47 (2001) 55-63
32. Salas-Puig J., Serratosa J.M., Viteri C., and Gil-Nágel Rein A. Grupo Español del Estudio SKATE Seguridad del levetiracetam como tratamiento adyuvante en la epilepsia: el estudio SKATE en España. Rev. Neurol. 38 (2004) 1117-1122
33. Shorvon S.D., Löwenthal A., Janz D., Loiseau P., and European Levetiracetam Study Group. Multicenter, double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia 41 (2000) 1179-1186
34. ®) as adjunctive therapy in patients with refractory epilepsy. Epilepsia 44 Suppl. 8 (2003) 153 (Abstract P463)
35. Steinhoff B.J., Trinka E., Wieser H.G., and for the DACH-LEV Study Group. Levetiracetam in patients with refractory epilepsy: results of the SKATE trial in Austria, Germany and Switzerland. Seizure 14 (2005) 490-496
36. Verdru P., Wajgt A., Schiemann Delgado J., and Noachtar S. Efficacy and safety of levetiracetam 3000 mg/d as adjunctive treatment in adolescents and adults suffering from idiopathic generalized epilepsy with myoclonic seizures. Epilepsia 46 Suppl. 6 (2005) 54-55 (Abstract 028)